By Derrick Gingery / Email the Author / Feb. 4, 2013
Executive Summary
Stakeholders say it would create more confusion in the pharmacy and regulatory community; they also spar over whether volume, other criteria should be imposed to distinguish compounding types.
to purchase and read this report click here
No comments:
Post a Comment